Compare Ascendis Pharma A/S (ASND) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Energy Select Sector SPDR Fund — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Energy Select Sector SPDR Fund trades at $55.7. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Energy Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ASND | XLE | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $62.57 |
52-Week Low | $163.32 | $42.12 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
XLE, the Energy Select Sector SPDR ETF, trades at $55.08, up 0.49% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF has gained 21% year-to-date as of July 2, 2026 (ETF Trends), benefiting from oil price volatility and geopolitical tensions. Recent news highlights sector strength, though oil price fluctuations and concentration in 21 holdings pose considerations.
Outlook remains supported by energy demand and disciplined capital expenditure, but risks include oil price sensitivity and political pressure. Analyst sentiment is mixed, with technical strength offsetting fundamental valuation gaps. The dividend yield and expense ratio advantages are positive, yet investors face volatility from crude market dynamics and election-related policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
